Why Nucor’s Stock Dip Could Be a Golden Opportunity in Disguise
Nucor (NYSE: NUE) isn’t just another steelmaker churning out metal for skyscrapers and rebar. It’s a powerhouse that has weathered economic storms, steel cycles, and shifting energy costs, all while steadily raising its dividend for over the past half century.
Yet, despite that remarkable consistency, investors seems to be snoozing on Nucor right now so is it time to buy?
» Read more about: Why Nucor’s Stock Dip Could Be a Golden Opportunity in Disguise »
Read More
What Oracle CEO Said 55 Hours Ago Will Shock You
I’m old enough to remember when Oracle was $13 per share in 2003 and by 2006 it was still $13 per share.
The company seemed as old and boring and stodgy as any tech company could become. It was almost like an IBM relic that would gather dust, selling software to enterprises and producing a boatload of cash flow but really doing nothing to excite investors or innovate.
» Read more about: What Oracle CEO Said 55 Hours Ago Will Shock You »
Read More
1 Weird Advantage NVIDIA Has Over Magnificent 7
In spite of recent share price turbulence, NVIDIA has been on an astonishing run over the past 5 years with the stock gaining a remarkable 2,317%.
To give you a sense of the magnitude of the bull run, NVIDIA’s revenues were $10 billion in 2020, but have soared to $60.9 billion in the intervening years.
» Read more about: 1 Weird Advantage NVIDIA Has Over Magnificent 7 »
Read More
1 Little-known Fund Goes All In On Semi Stock
Prospect Capital Advisors isn’t a big name fund but it’s put almost 10% of its fund into a single stock, Silicon Motion Technology.
For a fund overseeing hundreds of millions of dollars, this is quite a bet. Why risk it all on a little-known stock when you can follow the herd into Apple,
» Read more about: 1 Little-known Fund Goes All In On Semi Stock »
Read More
4% Dividend + 12x Earnings = Blockbuster in the Making
Merck has long been a pillar of stability in the pharmaceutical world, thanks in large part to the staggering success of its cancer drug Keytruda. But behind that success lies a quietly growing concern of what happens when the patents expire?
In a move that could reshape its future, Merck just announced a $10 billion acquisition of Verona Pharma.
» Read more about: 4% Dividend + 12x Earnings = Blockbuster in the Making »
Read MoreThe Burst
The Market Just Flashed a Rare Signal
Buying great companies regularly and keeping a cool head has proven to be a time-tested winning formula in the markets.
That said, every now and then, it’s worth paying attention when a technical signal with a track record like this flashes green.
Last week, the market delivered something truly rare: the triggering of the Zweig Breadth Thrust.
» Read more about: The Market Just Flashed a Rare Signal »
Read MoreThe Spotlight
Will Ford’s EV Gamble Pay Off?
As we race towards the end of 2024, a full 17 million electric vehicles are projected to be sold, which if realized will translate to a whopping 1 in 5 of all car sales.
With demand for EV’s as strong as ever and competition from Tesla and China’s BYD stiffening, what does the future hold for Ford and its EV strategy?
» Read more about: Will Ford’s EV Gamble Pay Off? »
Read MoreThe Daily
Tesla Shares Way Up Since First Big Money Buy, Keep Rising
Important DisclaimersFXEmpire is owned and operated by Empire Media Network LTD., Company Registration Number 514641786, registered at 7 Jabotinsky Road,
» Read more about: Tesla Shares Way Up Since First Big Money Buy, Keep Rising »